Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
A gastroenterologist reviews inflammatory bowel disease imaging and oral treatment options as cAMPfield Therapeutics advances prifemilast for ulcerative colitis and Crohn’s disease. Representative image.
Pharma & Biotech

Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?

Gilead Sciences agrees a $1.275 billion deal for HCXT-2001, an oral IL-23R inhibitor. Its IBD potential faces major clinical tests.

Read More
Editorial infographic highlighting Innate Pharma’s November 5, 2026 update, featuring a clinical research laboratory, immunotherapy imagery, a calendar, and key developments involving IPH4502, the Sobi partnership and monalizumab.
Pharma & Biotech

Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?

Innate Pharma plans its November 5 update as IPH4502 data, the Sobi partnership and monalizumab milestones approach. Key clinical questions remain.

Read More
Representative image of invasive aspergillosis research as F2G and Shionogi report positive Phase 3 olorofim results, highlighting its potential as a new oral antifungal treatment.
Pharma & Biotech

Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis

F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.

Read More
Representative image of uveitis research as Roivant Sciences and Priovant Therapeutics report positive Phase 3 brepocitinib results, reducing treatment failure and improving steroid-free disease control.
Pharma & Biotech

Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials

Roivant's brepocitinib succeeds in two Phase 3 uveitis trials, improving steroid-free disease control. Explore the results and FDA plans.

Read More
Representative image of ulcerative colitis research as Odyssey Therapeutics’ oral drug OD-001 achieves 27% clinical remission in a Phase 2a trial, showing promising treatment potential.
Pharma & Biotech

OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients

Odyssey Therapeutics reports 27% remission with OD-001 in Phase 2a ulcerative colitis testing. Explore the findings and next clinical trials.

Read More
Representative image of Parkinson’s disease research as BioVie’s bezisterim shows promising Phase 2 improvements in motor and non-motor symptoms among patients with elevated inflammation.
Pharma & Biotech

Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms

BioVie's bezisterim shows promising Phase 2 Parkinson's results in patients with elevated inflammation. Explore the findings and Phase 3 outlook.

Read More
Representative image of bipolar disorder clinical research as Rapport Therapeutics’ RAP-219 meets key Phase 2 trial endpoints, showing promising results in bipolar mania treatment.
Pharma & Biotech

Rapport Therapeutics’ RAP-219 delivers statistically significant bipolar mania improvements in Phase 2 trial

Rapport Therapeutics' RAP-219 meets Phase 2 bipolar mania endpoints. Explore its clinical results, safety findings and planned Phase 3 trials.

Read More
Editorial infographic showing TriGemX Bio’s planned $246 million SPAC transaction to support Phase 3 elismetrep trials, featuring laboratory imagery, clinical trial documents, financial charts, and key development milestones.
Pharma & Biotech

TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials

TriGemX Bio plans a $246 million SPAC transaction to fund Phase 3 elismetrep trials. Clinical results and deal completion will determine its future.

Read More
Editorial infographic showing Veradermics’ Phase 3 VDPHL01 hair growth study in 536 men, with hair follicle imagery, a clinical trial document, and references to efficacy, safety, and FDA review.
Pharma & Biotech

What the Veradermics Phase 3 results mean for oral minoxidil treatment

Veradermics reports strong Phase 3 VDPHL01 hair growth results in 536 men. Efficacy is encouraging, but safety and FDA review remain crucial.

Read More
Editorial infographic illustrating Summit Therapeutics’ global Phase 2 kidney cancer trial, featuring anatomical kidney imagery, a clinical trial document, a world map, and highlights of ivonescimab combination therapies compared with established immunotherapy.
Pharma & Biotech

Summit Therapeutics expands ivonescimab development with SMT112-216 trial

Summit Therapeutics opens a global Phase 2 kidney cancer trial testing ivonescimab combinations against established immunotherapy. What comes next?

Read More